Information Provided By: 
Fly News Breaks for January 8, 2019
SRPT
Jan 8, 2019 | 09:05 EDT
Baird analyst Brian Skorney admitted Sarepta missed an opportunity to impress with their presentation at the JPMorgan healthcare conference, but he thinks the stock reaction is unwarranted. Microdystrophin timelines look consistent and management remains enthusiastic about LGMD data in Q1 and has not seen any expression data yet, said Skorney. He thinks the data is highly likely to be positive and expects the stock to reverse its course. Skorney reiterated his Outperform rating and $202 price target on Sarepta shares.
News For SRPT From the Last 2 Days
There are no results for your query SRPT
